660823-36-9

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO INDAZOLE-3-CARBOXYLIC ACID is used as a key intermediate in the synthesis of indazole derivatives, which are potent hepcidin production inhibitors. Hepcidin is a hormone that regulates iron homeostasis in the body, and its inhibition can be beneficial in the treatment of anemia of chronic diseases (ACD). By targeting the hepcidin pathway, these indazole derivatives can help alleviate the symptoms of ACD and improve the quality of life for patients suffering from this condition.

InChI:InChI=1/C8H5BrN2O2/c9-4-1-2-5-6(3-4)10-11-7(5)8(12)13/h1-3H,(H,10,11)(H,12,13)

Upstream product

• 6326-79-0 6-bromoisatin 
• 7099-87-8 4-bromophenylglyoxylic acid 
• 885278-42-2 6-bromo-1H-indazole-3-carboxylic acid methyl ester 

Downstream Products

• 660823-03-0 6-bromo-1H-indazole-3-carboxylic acid (4-fluorophenyl)amide 
• 885278-42-2 6-bromo-1H-indazole-3-carboxylic acid methyl ester 
• 1296202-90-8 C₁₆H₁₄BrN₃O 
• 1228450-67-6 N-methyl-6-(4-(pyridazine-4-carboxamido)phenyl)-1H-indazole-3-carboxamide 
• 1228451-69-1 6-(4-aminophenyl)-N-methyl-1H-indazole-3-carboxamide 
• 1228451-67-9 N-methyl-6-(4-nitrophenyl)-1H-indazole-3-carboxamide 
• 1228451-65-7 6-(4-nitrophenyl)-1H-indazole-3-carboxylic acid 
• 1228450-53-0 N-(2-morpholinoethyl)-6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxamide 
• 1228450-43-8 N-methyl-6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxamide 
• 1228451-63-5 6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxylic acid 
• 1228450-38-1 ethyl 6-(4-(3-(3,4-dichlorophenyl)ureido)phenyl)-1H-indazole-3-carboxylate 
• 1228450-07-4 ethyl 6-(4-(3-(trifluoromethyl)benzamido)phenyl)-1H-indazole-3-carboxylate 
• 1228450-05-2 ethyl 6-(4-aminophenyl)-1H-indazole-3-carboxylate 
• 1228451-61-3 1-tert-butyl 3-ethyl-6-(4-nitrophenyl)-1H-indazole-1,3-dicarboxylate 

Relevant academic research and scientific papers

From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor

Fibroblast growth factor receptors (FGFRs) are implicated in a range of cancers with several pan-kinase and selective-FGFR inhibitors currently being evaluated in clinical trials. Pan-FGFR inhibitors often cause toxic side effects and few examples of subtype-selective inhibitors exist. Herein, we describe a structure-guided approach toward the development of a selective FGFR2 inhibitor. De novo design was carried out on an existing fragment series to yield compounds predicted to improve potency against the FGFRs. Subsequent iterative rounds of synthesis and biological evaluation led to an inhibitor with nanomolar potency that exhibited moderate selectivity for FGFR2 over FGFR1/3. Subtle changes to the lead inhibitor resulted in a complete loss of selectivity for FGFR2. X-ray crystallographic studies revealed inhibitor-specific morphological differences in the P-loop which were posited to be fundamental to the selectivity of these compounds. Additional docking studies have predicted an FGFR2-selective H-bond which could be utilized to design more selective FGFR2 inhibitors.

INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities

Aberrant activation of p21-activated kinase 1 (PAK1) is associated with tumour progression, and PAK1 has been recognized as a promising target for anticancer drug discovery. However, the development of potent PAK1 inhibitors with satisfactory kinase selec

INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor

The histone acetyltransferases, CREB binding protein (CBP) and EP300, are master transcriptional co-regulators that have been implicated in numerous diseases, such as cancer, inflammatory disorders, and neurodegeneration. A novel, highly potent, orally bioavailable EP300/CBP histone acetyltransferase (HAT) inhibitor, CPI-1612 or 17, was developed from the lead compound 3. Replacement of the indole scaffold of 3 with the aminopyridine scaffold of 17 led to improvements in potency, solubility, and bioavailability. These characteristics resulted in a 20-fold lower efficacious dose for 17 relative to lead 3 in a JEKO-1 tumor mouse xenograft study.

Pyrazolopyridine or indazole derivatives as protein kinase inhibitors

The present invention relates to novel pyrazolopyridine or indazole derivatives having inhibitory activity against protein kinases or pharmaceutically acceptable salts thereof. Since compounds of the present invention have excellent inhibitory activity against to protein kinases, for example, ABL, ACK1, ALK, Aurora A, Aurora B, Aurora C, BLK, BMX/ETK, BRSK1, BTK, c-Src, CAMKK, CDK1, CDK2, CDK5, CLK, DDR, DYRK1B, EPHA, EPHB, FAK/PTK2, FER, FES/FPS, FGFR, FGR, FLT3, FLT4/VEGFR3, FMS, FRK/PTK5, FYN, GSK3b, HCK, IGF1R, IR, IRAK1, IRR/INSRR, ITK, JAK2, KHS/MAP4K5, LCK, LYN, PHKg, PLK4/SAK, PYK2, RET, ROS/ROS1, TIE2/TEK, TRK, TXK, TYK, YES/YES1, and the like, the compounds are useful for treatment and prevention of various kinds of cancer diseases.

P300/CBP HAT INHIBITORS

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.